Abstract
LMWH are standardized with reference to inhibitory activity against factor Xa. Nevertheless, in these agents, higher anti-Xa activity is no associated with higher antithrombotic effect.
LMWHs are used in many branches of medicine. Unlike unfractionated heparins, LMWH have proved effective in transplant recipients, for treatment and prevention of vascular occlusion in cancer patients, in cerebral thromboembolism and in prophylaxis and treatment of deep venous thrombosis in CAD patients.
By specifically blocking smooth muscle cell (SMC) receptors and thus preventing SMC proliferation, LMWHs are beneficial in patients after coronary angioplasty.